Neoadjuvant Nivolumab ' Promising ' in Merkel Cell Carcinoma Neoadjuvant Nivolumab ' Promising ' in Merkel Cell Carcinoma

A longer follow-up and larger cohort are needed, but results from a new study showed safety and a survival benefit among patients who received nivolumab as an adjunct to surgery.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news